What is RT (Reta)? A Research Overview

What is RT (Reta)? A Research Overview

This article is intended for research and educational purposes only. Retatrutide is an investigational compound and is not approved for human self-administration outside of licensed clinical settings. All references to research use refer to controlled laboratory and preclinical study contexts.

What is RT (Reta)?

RT (Reta) is a synthetic peptide developed by Eli Lilly and currently under clinical investigation. It is the first known triple hormone receptor agonist, simultaneously targeting three receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). This triple-agonist profile makes it a structurally and pharmacologically distinct compound from earlier dual-agonists such as TR.

In research settings, RT (Reta) is studied for its unique multi-receptor mechanism and its potential implications for metabolic science.

Mechanism of Action

RT (Reta) binds to and activates three incretin and metabolic hormone receptors simultaneously:

  • GLP-1R activation — stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying
  • GIPR activation — enhances insulin sensitivity and modulates adipose tissue metabolism
  • Glucagon receptor (GCGR) activation — increases energy expenditure and promotes hepatic fat oxidation

The addition of glucagon receptor agonism is the key differentiator from dual-agonist compounds. Researchers are particularly interested in how GCGR activation contributes to energy expenditure independently of caloric restriction, and how the three pathways interact at a systems level.

Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM. → Read study

Research Background

RT (Reta) emerged from efforts to build on the success of dual GIP/GLP-1 agonists by adding a third metabolic lever. Key areas of ongoing research interest include:

  • Energy expenditure modelling — investigating how glucagon receptor co-activation affects basal metabolic rate in preclinical and clinical models
  • Hepatic metabolism — early research into effects on liver fat content and lipid metabolism
  • Body composition — Phase 2 data examining lean mass preservation alongside fat mass reduction
  • Receptor interaction pharmacology — understanding how simultaneous tri-receptor agonism affects downstream signalling compared to mono- and dual-agonist compounds

How RT (Reta) Differs from Dual Agonists

TR (dual GIP/GLP-1) represented a significant step forward from single-receptor GLP-1 agonists. RT (Reta) adds glucagon receptor agonism as a third mechanism, which researchers hypothesise may:

  • Drive additional energy expenditure beyond appetite suppression alone
  • Produce additive or synergistic effects on fat oxidation
  • Offer a distinct pharmacological profile for studying metabolic disease models

Coskun T, et al. (2022). Semaglutide, liraglutide, and tirzepatide exhibit distinct effects on body composition in diet-induced obese mice. Obesity. → Read study

Certificate of Analysis & Purity

For research use, purity and identity verification are essential. When sourcing Retatrutide for laboratory work, researchers should review the Certificate of Analysis (CoA) for:

  • HPLC purity — research-grade material is generally ≥98%
  • Mass spectrometry confirmation — verifying molecular weight matches the expected value for Retatrutide (MW ~4,973 Da)
  • Appearance and solubility — lyophilised powder, typically white to off-white

Storage Guidance

RT (Reta) in lyophilised form should be stored according to standard peptide cold-chain protocols. Once reconstituted:

  • Short-term (in use): 2–8°C (refrigerated) for up to 30 days
  • Keep out of direct sunlight
  • Do not shake — invert gently to mix

Further Reading

View our RT (Reta) Peptide – For Research Purposes Only product page for full specifications and CoA information.

 

All products sold by Healthy Life Happy Minds are strictly for in-vitro research and laboratory use only. They are not intended for human or veterinary use, self-administration, or therapeutic application.

References

The following references were accurate at the time of publishing. We recommend verifying links are still active, as URLs and journal access policies may change over time.

  1. Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. doi.org/10.1056/NEJMoa2301972
  2. Coskun T, et al. (2022). Semaglutide, liraglutide, and tirzepatide exhibit distinct effects on body composition in diet-induced obese mice. Obesity. doi.org/10.1002/oby.23540